Skip to main content
Clinical Trials/NCT06168357
NCT06168357
Not yet recruiting
Not Applicable

Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma Following Locoregional Treatment.

Assiut University0 sites55 target enrollmentJanuary 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hepatocellular Carcinoma
Sponsor
Assiut University
Enrollment
55
Primary Endpoint
Correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Role of ADC value and DWI in abbreviated MRI compared to post-contrast CT in follow-up of HCC after TACE.

Detailed Description

Hepatocellular carcinoma (HCC) is the 5th most common cancer in the world and the most common in Egypt . Trans-arterial chemoembolization (TACE) is the treatment recommended for unresectable HCC according to Barcelona clinic liver cancer staging and is widely used . HCC is nourished only by the hepatic artery, so TACE causes ischemia and coagulative necrosis. However; viable neoplastic tissue residual may be seen after TACE. Assessment of post-TACE tumor response is important in determining treatment success and in guiding future therapy . Many studies have assessed the diagnostic performance of multiphasic contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) in diagnosis of HCC with noted higher sensitivity of MRI compared to CT. CT or MRI are recommended for assessment of response after treatment as well . Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) are functional MRI techniques that detect signal changes in tissues due to water proton motion. The intact membranes of viable tumor cells restrict water diffusion, whereas necrotic tumor cells with disrupted cell membranes exhibit increased water diffusion and which differentiate the biological activity of HCC

Registry
clinicaltrials.gov
Start Date
January 2024
End Date
September 30, 2027
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nour Mokhles Farah

Assistant Lecturer

Assiut University

Eligibility Criteria

Inclusion Criteria

  • Patients who underwent TACE for unresectable HCC with patent portal vein based on Doppler, no ascites, and satisfactory liver function.
  • Age between 20-year old and 85-year old

Exclusion Criteria

  • Estimated GFR less than 60 Previous history of severe allergic reaction to the iodinated contrast agent Patients with claustrophobia who can't undergo MR examination. Patients having cochlear implants or cardiac pacemaker

Outcomes

Primary Outcomes

Correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.

Time Frame: Baseline

correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.

Similar Trials